Emma Andrus - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Emma Andrus's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Emma Andrus
Verified
Assistant Editor, Dermatology Times
Cleveland
Beats
Neurodiversity, racial, Gender And Women's Issues , Islam , Spirituality, Adhd , Chronic Illness, Ethnic And Cultural Issues, Identity Politics, Mental Health , Malaysian Politics, Autism, Disability
Health.
Content
By Emma Andrus| Dermatology Times Verified To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. QRPs are key to dermatologists' retirement plans—learn the benefits, drawbacks, and how to choose the best strategy for your financial goals. Spearheaded by John Zampella, MD, FAAD, and Mitchell Hanson, the project highlights how art can foster community and empathy in dermatology. Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.
Gene Expression Profile Testing Offers Clinicians a Path to Safely Avoid SLNB in Low-Risk Melanoma Patients
By Emma Andrus| Dermatology Times Verified A new analysis from the prospective, multicenter DECIDE study, recently published in Cancer Medicine, found that patients with cutaneous melanoma and a Class 1A 31-gene expression profile (31-GEP) result had a 100% 3-year recurrence-free survival rate, even when sentinel lymph node biopsy (SLNB) was not performed.
By Emma Andrus| Dermatology Times Verified To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. QRPs are key to dermatologists' retirement plans—learn the benefits, drawbacks, and how to choose the best strategy for your financial goals. Spearheaded by John Zampella, MD, FAAD, and Mitchell Hanson, the project highlights how art can foster community and empathy in dermatology. Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.
Company Info
Dermatology Times
Dermatology Times is a prominent news resource and weekly newsmagazine dedicated to dermatologists and skin care professionals. Based in Cranbury, US, with operations in North Olmsted, Ohio, the company provides timely clinical insights, regulatory news, and practice management strategies. It covers the latest developments in dermatology, including breakthrough treatments and emerging trends. The company also hosts educational events and conferences, such as the "Revolutionizing Atopic Dermatitis (RAD) Conference" and the "Cases and Conversations" series, focusing on various dermatological conditions. Additionally, Dermatology Times features a weekly crossword puzzle that combines dermatology knowledge with entertainment, helping professionals reinforce their expertise. With a readership of over 16,000 dermatologists and skin care professionals, Dermatology Times plays a vital role in keeping practitioners informed and engaged in their field.
'+1 609-716-7777
Founded: 1979